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TIMP-1We investigated whether three relevant polymorphisms (C-1562T, microsatellite−90(CA)14–24, and Q279R)
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MMP-9 concentrations than patients with MA. Patients with MA had the highest TIMP-1 and lowest MMP-9/
TIMP-1 ratios. The MMP-9 “C L Q” haplotype was associated with higher plasma MMP-9 concentrations in
migraine patients.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Migraine is a chronic, intermittent, neurological disorder associated
with a complex combination of cerebral and vascular events
(Moskowitz, 2007; Goadsby et al., 2009; Markus Schürks et al., 2009).
In this context, a neurovascular hypothesis has been proposed to explain
the pathophysiology of migraine (Schurks et al., 2009), although the
precise event responsible for migraine attacks still remains incompletely
understood (Pietrobon and Striessnig, 2003). In this respect, the disrup-
tion of the blood–brain barrier (BBB) has been implicated during a
migraine attack (Leira et al., 2007; Imamura et al., 2008). Despite no
clear evidence of BBB proteolysis during migraine attacks (Edvinsson
and Tfelt-Hansen, 2008), experimental induction of cortical spreading
depression showed that breakdown of BBB may result of matrix
metalloproteinases (MMP)-dependent mechanisms (Gursoy-Ozdemir et
al., 2004).
MMPs are a large family of zinc-dependent enzymes involved in the
degradation of a wide spectrum of extracellular matrix proteins. Their
activation and activity is modulated by endogenous inhibitors, the tissueology, Faculty of Medicine of
tes, 3900, 14049-900 Ribeirao
3602 0220.
ahoo.com (J.E. Tanus-Santos).
y.
vier OA license.inhibitors of MMP (TIMPs), and imbalanced MMP activities have been
suggested as relevant pharmacological targets inmany disease conditions
(Castro et al., 2011; Fontana et al., 2012; Marson et al., 2012; Romi et al.,
2012). Importantly, MMP-9 has been implicated as a major mediator of
BBB disruption in neuroinﬂammatory conditions that may promote
migraine (Montaner et al., 2001; Castellanos et al., 2003; Gursoy-
Ozdemir et al., 2004; Gurney et al., 2006). Indeed, experimental studies
with MMP-9 knockout mice showed reduced BBB leakage and edema
formation (Asahi et al., 2001), thus strongly indicating that MMP-9 is
very important for this process. Moreover, previous studies showed in-
creased circulating MMP-9 levels in migraine patients (Leira et al.,
2007; Imamura et al., 2008), and it is possible that circulating MMP-9
levels may reﬂect migraine attacks (Leira et al., 2007; Imamura et al.,
2008; Martins-Oliveira et al., 2009). However, it is not known whether
genetic variations in theMMP-9 genemay affect the susceptibility to mi-
graine and whether there are subgroups of patients that are genetically
exposed to increased MMP-9 levels as a result of genetic differences.
Such patients would potentially beneﬁt from MMPs inhibitors.
Mounting evidence suggests that MMP-9 gene polymorphisms may
affect MMP-9 levels, the progression of disease conditions and thera-
peutic responses (Demacq et al., 2009; Jacob-Ferreira et al., 2010b;
Lacchini et al., 2010; Belo et al., 2012; Palei et al., in press). Relevant
functional MMP-9 polymorphisms include the C(−1562)T polymor-
phism (Zhang et al., 1999), a microsatellite−90(CA)n (13–25 repeats)
in promoter region (Shimajiri et al., 1999), and the Q279R in exon 6
(Allan et al., 1995). Therefore, in the present study, we examined
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associated with migraine or with altered MMP-9 concentrations in mi-
graine patients. We have also studied the TIMP-1 concentrations and
MMP-9/TIMP-1 ratio, which may provide a better index of net MMP-9
activity.
2. Materials and methods
2.1. Subjects
This study was approved by the Ethics Committee at Faculty of
Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. After complete
description of nature of the study, eachparticipant gavewritten informed
consent.
We enrolled a total of 187 women with migraine and 102 healthy
women without history of migraine. Among them, 141 women were
diagnosed with migraine without aura (MWA) and 46 with aura (MA).
Migraine patients were enrolled at the Headache Clinic of the Neurology
Department, University Hospital of the Faculty of Medicine of Ribeirao
Preto, University of Sao Paulo. Diagnosis of migraine wasmade according
to the International Classiﬁcation of Headache Disorders criteria Anon
(2004).
All study subjects were of Brazilian origin and underwent a complete
medical history and physical examination. Furthermore, we excluded
patients with preexistent diseases, pregnant as well as other kinds of
headache. The control group included healthy womenwithout headache
were randomly selected from the local population visiting our University
for non-medical reasons and unrelated to the patients.
2.2. Biochemical measurements
After written, informed consent was obtained, venous blood samples
were collected into vacutainer plastic tubes (Becton-Dickinson, Brazil)
containing sodium/potassium EDTA. We collected blood samples from
patients either in the interictal phase or under migraine attack because
previous results showed no differences in MMPs, TIMPs, or MMPs/
TIMPs ratioswhenMAorMWApatientswith headache attackwere com-
pared with asymptomatic MA or MWA patients, respectively (Martins-
Oliveira et al., 2009). The blood samples were centrifuged at 1000×g
for 10 min. The plasma samples were separated and immediately stored
at−70 °C until used to measure plasma MMP-9 and TIMP-1 concentra-
tions. In addition, aliquots of whole blood were separated and stored at
−20 °C for genomic DNA extraction.
2.3. DNA isolation and genotype analyses
Genomic DNA was obtained from the cellular component of 1 mL of
whole blood by a salting-outmethod and stored at−20 °C until analysis.
To determine the genotypes for the −90(CA)14–24 (rs2234681) poly-
morphism, a PCR was carried out using the primers: 5′-GAC TTG GCA
GTG GAG ACT GCG GGC A-3′ (sense) e 5′-GAC CCC ACC CCT CCT TGA
CAG GCA A‐3′ (antisense) (Demacq et al., 2008). The PCR conditions
were performed as previously described (Demacq et al., 2008) and the
ampliﬁed products were separated in a 7% polyacrylamide-urea gel and
visualized by silver staining. Differences in molecular weight (or number
of bases), from 146 bp (CA 14 repeats) to 166 bp (CA 24 repeats) were
determined by comparison with migration of a 10 bp DNA ladder
(Invitrogen, Carlsbad, CA, USA) and with some samples from homozy-
gotes that were sequenced. The alleles for the microsatellite −90(CA)
14–24 polymorphism were classiﬁed as “low” (L) count when the num-
ber of CA repeatswas less than 21, and as “high” (H)when the number of
CA repeats was 21 or more (Demacq et al., 2009).
Genotypes for the (C-1562T (rs3918242)) polymorphism of MMP-9
were determined by polymerase chain reaction (PCR) ampliﬁcation
using the primers 5′-GCC TGG CAC ATA GTA GGC CC-3′ (sense) and
5′-CTT CCT AGC CAG CCG GCA TC-3′ (antisense) and PCR conditionsas previously described (Demacq et al., 2006, 2008). The ampliﬁed
products were digested with Sph I (New England Biolabs, Ipswich,
MA, USA) overnight at 37 °C, producing fragments of 247 bp and
188 bp in the case of a polymorphic variant (allele T), or an undigested
435 bp band in the case of a wild type allele (allele C) (Jacob-Ferreira et
al., 2010b). Fragments were separated by electrophoresis in 12% poly-
acrylamide gels and visualized by silver staining.
Genotypes for Q279R (rs17576) were determined using TaqMan®
Allele Discrimination assay (Applied Biosystems, Foster City, CA). The
PCR conditions were performed according to appointed by
manufacturer's instructions.
2.4. Determination of plasma MMP-9 and TIMP-1 levels
To investigate the effects of MMP-9 polymorphisms or haplotypes
on the circulating levels of MMP-9, we measured the plasma MMP-9
concentrations using a commercially available enzyme-linked immu-
nosorbent assay (R&D Systems, Inc., Minneapolis MN) according to
manufacturer's instructions. Moreover, we measured the plasma con-
centrations of TIMP-1 using commercially available enzyme-linked
immunosorbent assays (R&D Systems, Inc., Minneapolis MN) and cal-
culated the MMP-9/TIMP-1 ratio because this ratio may be a better
index of net MMP-9 activity (Belo et al., 2009).
2.5. Haplotype inference
Haplotypeswere inferredusing the Bayesian statistical basedprogram
PHASE version 2.1 (http://www.stat.washington.edu/stephens/software.
html) (Stephens et al., 2001) to estimate the haplotype frequencies in
the population and themost likely pairs of haplotypes for each individual
(Table 4). The possible haplotypes including genetic variants for three
MMP-9 polymorphisms studied (H or L variants for −90(CA) 14–24, C
or T variants for the C-1562T and Q or R variants for Q279R) were: H1
(CLR), H2 (CHR), H3 (CHQ), H4 (THQ), H5 (TLR), H6 (CLQ), H7 (THR)
and H8 (TLQ). Therefore, we evaluated whether MMP-9 haplotypes
modulate circulating MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio among
studied groups. However, due to low frequency of theH7 andH8 haplo-
types, we excluded them of analysis. To assess differences in haplotype
frequency distributionswasused chi-square test, and to compare haplo-
type frequencies in controls and migraine a value of pb0.00625 (0.05/
number of haplotypes) was considered signiﬁcant to correct for the
number of comparisons made.
2.6. Statistical analysis
The clinical data of study participants were compared by Kruskall-
Wallis test followed, by Dunn's multiple comparison test for continuous
variables and were expressed as mean±standard deviation. Categorical
variables were compared by Fisher's exact test or χ2 test and expressed
as frequencies and percentages (StatView, Cary, NC, USA).
The distribution of genotypes for each polymorphism was examined
for deviation from the Hardy-Weinberg equilibrium by using chi-
squared tests (StatView, Cary, NC, USA). Differences in the genotype
and allele frequencies of each polymorphism among the groupswere an-
alyzed using chi-squared tests. In function of the relatively low frequency
of the TT genotype, we combined both TT and CT genotypes (CT+TT
group) to compare the effect of the genotypes on MMP-9 plasma levels.
A value of pb0.05 was considered the minimum level of statistical
signiﬁcance.
3. Results
The data regarding clinical characteristics of the individuals enrolled
in the present study population are summarizes in Table 1. There were
no signiﬁcant differences in the clinical parameters among groups
(p>0.05).
Table 2
MMP-9 genotype and allele distributions.
Polymorphism Genotypes Controls
(n=102)
Migraine
All (n=
187)
MWA (n=
141)
MA (n=
46)
−90(CA)n LL 0.196 (20) 0.246 (46) 0.248 (35) 0.239 (11)
HL 0.510 (52) 0.487 (91) 0.482 (68) 0.500 (23)
HH 0.294 (30) 0.267 (50) 0.270 (38) 0.261 (12)
C-1562T CC 0.794 (81) 0.839 (157) 0.851 (120) 0.804 (37)
CT 0.177 (18) 0.150 (28) 0.142 (20) 0.174 (8)
TT 0.029 (3) 0.011 (2) 0.007 (1) 0.022 (1)
R(279)Q RR 0.480 (49) 0.476 (89) 0.490 (69) 0.435 (20)
RQ 0.402 (41) 0.406 (76) 0.411 (58) 0.391 (18)
QQ 0.118 (12) 0.118 (22) 0.099 (14) 0.174 (8)
Alleles
−90(CA)n L 0.451 (92) 0.489 (183) 0.489 (138) 0.489 (45)
H 0.549 (112) 0.511 (191) 0.511 (144) 0.511 (47)
C-1562T C 0.882 (180) 0.914 (342) 0.922 (260) 0.891 (82)
T 0.118 (24) 0.086 (32) 0.078 (22) 0.109 (10)
R(279)Q R 0.681 (139) 0.679 (254) 0.695 (196) 0.630 (58)
Q 0.319 (65) 0.321 (120) 0.305 (86) 0.370 (34)
MWA, migraine without aura; MA, migraine with aura.
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compared with MA patients (pb0.05; Table 1). In addition, we found
higher plasma TIMP-1 concentrations in the MA group of women with
MA compared with those found in MWA and the control group
(pb0.05; Table 1). Interestingly, we found that women with MA had
lower MMP-9/TIMP-1 ratios when compared with MWA and with the
control group (pb0.05; Table 1).
Table 2 shows the genotype and allele distributions in migraine
and control groups. The distribution of genotypes for the three poly-
morphisms evaluated in this study showed no deviation from
Hardy-Weinberg equilibrium in both case and control groups. We
found no signiﬁcant difference in the genotype and allelic distribution
for the three MMP-9 polymorphisms when patients and controls
were compared (p>0.05).
We examined the effects of MMP-9 polymorphisms on plasma
MMP-9 concentrations in the three study grups (Table 3). While we
found no major effects of genotypes on plasma MMP-9 levels in the
three study groups (p>0.05; Table 3), we found lower MMP-9 levels
in patients with the CT or TT genotypes for the C-1562T polymorphism
in the MA group than in controls or in MWA patients (pb0.05; Table 3).
We estimatedhaplotype frequencies in the three groups (Table 4).We
found no signiﬁcant differences in the distribution of MMP-9 haplotype
frequencies when the three groups were compared (p>0.05; Table 4).
Interestingly, the analysis of how MMP-9 haplotypes affect MMP-9
levels in plasma showed the slightly higher MMP-9 levels in healthy
subjects carrying the H4 (T H Q) haplotype compared with the other
haplotypes (pb0.05; Fig. 1A). While no signiﬁcant effects were found
for MMP-9 haplotypes on plasma MMP-9 in the MWA and in the MA
groups (p>0.05; Fig. 1C and D, respectively), the H6 haplotype was as-
sociated with the highest MMP-9 levels when all migraine patients
were combined (pb0.05; Fig. 1C).
Finally, the analysis of TIMP-1 levels and MMP-9/TIMP-1 ratios
showed no effects of MMP-9 haplotypes in the three groups (p>0.05;
Figs. 2 and 3, respectively).Table 1
Clinical characteristics of study participants.
Variables Controls MWA MA p
value
N 102 141 46 –
Age (years) 36.3±11.2 38.4±11.3 39.2±10.2 0.188
BMI (kg/m2) 26.4±5.3 27.2±5.8 26.2±5.7 0.617
Smoking (%) 20.4 24.0 17.3 0.620
Family history (%) – 68.2 82.6 0.084
Frequency (%)
1 to 3 per month – 10.8 15.2 0.436
3 to 5 per month – 18.6 8.7 0.159
5 to 10 per month – 11.6 19.6 0.212
10 to 15 per month – 24.1 19.6 0.683
> 15 days per month – 34.9 36.9 0.858
Intensity of attacks (%)
Mild – – 4.3 0.068
Moderate – 32.6 26.1 0.461
Severe – 67.4 69.6 0.855
Pain free (%) – 48.8 45.6 0.734
Under migraine
attack (%)
– 51.2 54.4
Ethnicity (%)
Whites 69.3 62.5 58.7 0.444
Non-whites 30.7 37.5 41.3
MMP-9 (ng/ml) 213.5±168.0 219.2±157.0⁎ 159.3±118.1 b0.05
TIMP-1 (ng/ml) 394.2±158.7 374.8±145.9 515.1±155.7⁎⁎ b0.05
MMP-9/TIMP-1 ratio 0.641±0.595 0.665±0.501 0.374±0.399⁎⁎ b0.05
BMI, body mass index; MWA, migraine without aura; MA, migraine with aura. Values
are the mean±S.D. or % number of subjects.
⁎ pb0.05 vs. MA.
⁎⁎ pb0.05 vs. controls and MWA.4. Discussion
While most previous studies have focused on the possible predic-
tive value of circulating MMP-9 levels in migraine attacks, this is the
ﬁrst study to investigate the possible association of functional MMP-9
polymorphisms with migraine. Moreover, no previous studies have
examined how combinations of genetic markers (haplotypes) in the
MMP-9 gene affect the circulating MMP-9 levels, or another relevant
index of net MMP-9 activity (MMP-9/TIMP-1 ratio). The main ﬁnding of
the present study is that a speciﬁcMMP-9 haplotype “C L Q” is associated
with high MMP-9 concentrations in patients with migraine, although we
found no signiﬁcant associations between MMP-9 genetic polymor-
phisms and migraine. This ﬁnding may have relevant pharmacogenetic
implications including the identiﬁcation of a particular group of migraine
patients that may beneﬁt from the use of MMPs inhibitors.
Although we have not investigated the molecular mechanisms
explaining how migraine patients carrying the “C L Q” haplotype have
higher MMP-9 levels, we could speculate that enhanced MMP-9 levels
associated with this haplotype may predispose these patients to in-
creased vascular BBB permeability, thus promoting the development
of an inﬂammatory environment in their central nervous systems,
which contributes to migraine attacks (Gursoy-Ozdemir et al., 2004).
Interestingly, we found that MMP-9/TIMP-1 tended (pb0.10) to be
higher in subjects with migraine carrying the “C L Q” haplotype, thus
suggesting that this haplotype associated with increased MMP-9 levels
is possibly also associated with increased net MMP-9 activity (Belo et
al., 2009; Fontana et al., 2011). It is possible that the increased MMP-9
levels found in these subjects may result in impaired BBB integrity be-
cause clinical (Castellanos et al., 2003; Rosell et al., 2006) and experi-
mental (Sumii and Lo, 2002) studies suggest that MMP-9 is critically
implicated in this alteration.
Previous studies reported enhanced plasma MMP-9 levels in
migraine patients, either between or during migraine attacks (Leira et
al., 2007; Imamura et al., 2008). Our ﬁndings reported here show
increased MMP-9 levels in patients with MWA compared to patients
with MA, and these ﬁndings are very similar to those previously shown
in a smaller study (Martins-Oliveira et al., 2009). Interestingly, we
found that MA patients, but not MWA patients, had lower MMP-9 and
higher TIMP-1 concentrations than healthy controls, thus suggesting
that higher TIMP-1 levels could be associatedwithMMP-9 plasma reduc-
tion in MA patients, although we have not determined the mechanisms
possibly involved in these differences. Another study showed that
MMP-9 levels were not correlated with the frequency or duration of
Table 3
Effects of genotype on plasma MMP-9 concentrations in controls and in migraine patients.
Polymorphism Genotype Controls (n=102) Migraine P
All (n=187) MWA (n=141) MA (n=46)
−90(CA)n LL 150.9 (100.2–404.4) 179.4 (126.2–275.6) 181.3 (133.6–274.6) 164.2 (73.8–434.6) ns
HL 162.1 (115.7–229.0) 155.3 (95.1–256.5) 164.7 (99.9–265.5) 105.6 (68.8–172.1) ns
HH 176.3 (101.9–332.9) 156.6 (100.2–267.1) 180.8 (101.7–320.0) 120.5 (85.7–162.4) ns
C-1562T CC 153.8 (105.1–244.7) 163.4 (100.1–258.0) 166.6 (107.8–266.2) 146.6 (73.2–212.5) ns
CT+TT 183.2 (130.0–348.5) 151.2 (103.1–292.3) 240.6 (121.5–382.8) 103.3⁎ (86.0–140.8) 0.016
R(279)Q RR 170.6 (113.5–336.8) 171.8 (102.7–250.1) 177.6 (116.2–250.1) 124.4 (61.2–261.7) ns
RQ 144.8 (91.2–191.2) 152.2 (95.6–260.2) 162.4 (97.7–282.8) 113.8 (71.8–169.4) ns
QQ 182.9 (124.5–408.8) 161.5 (114.7–368.8) 302.7 (137.4–467.3) 140.8 (94.0–162.4) ns
MWA, migraine without aura; MA, migraine with aura. Values are expressed as median (interquartile range).
⁎ pb0.05 vs. control group and MWA (Kruskall–Wallis test).
Table 4
Estimated MMP-9 haplotype frequencies in the control group and in migraine patients.
Haplotypes Controls Migraine MWA MA
H1 CLR 0.429 (87) 0.453 (170) 0.442 (125) 0.467 (43)
H2 CHR 0.249 (51) 0.226 (84) 0.253 (71) 0.163 (15)
H3 CHQ 0.186 (38) 0.203 (76) 0.184 (52) 0.240 (22)
H4 THQ 0.112 (23) 0.082 (31) 0.073 (21) 0.108 (10)
H5 TLR – – – –
H6 CLQ 0.021 (4) 0.033 (12) 0.043 (12) 0.021 (2)
H7 THR 0.003 (1) – – –
H8 TLQ – 0.003 (1) 0.005 (1) –
MWA, migraine without aura; MA, migraine with aura.
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ferences between studies may explain differences in MMP-9 levels. For
example, we included only women in our present study, and this is not
the case in many other studies which included both men and women.Fig. 1. Effects of MMP-9 haplotypes on plasma MMP-9 concentrations in the control (Panel
(MA; Panel D) groups. The box and whisker plots show range and quartiles. The boxes exten
kers show the highest and the lowest values. #pb0.05 for H4 vs. H3 (panel A). *pb0.05 forMoreover, it is possible that many environmental factors may also affect
MMP-9 levels (Jacob-Ferreira et al., 2009, 2010a).
Another potential implication of the present ﬁndings is thatmigraine
patients carrying the “C LQ” haplotypemay be exposed at increased car-
diovascular risk. Indeed, it is widely acknowledged that migraine affects
the risk of cardiovascular events (Kurth et al., 2006; Bigal et al., 2009).
Whether patients with migraine carrying the “C L Q” haplotype are ex-
posed to increased cardiovascular risk associatedwith this speciﬁc hap-
lotype is unknown. However, this suggestion is supported by growing
evidence indicating that increased circulatingMMP-9 levels are propor-
tionally associated with increased cardiovascular risk (Garvin et al.,
2008). Indeed, a complex long term study would be required to test
this hypothesis. However, if this hypothesis is proven true, migraine
patients with the “C L Q” haplotype would clearly beneﬁt from the use
of MMPs inhibitors.
Some limitations of the present study should be considered. Firstly,
there were differences in the number of subjects in each group, and
this may have decreased the power to detect signiﬁcant differencesA), migraine (Panel B), migraine without aura (MWA; Panel C) and migraine with aura
d from the 25th percentile to the 75th percentile, with a line at the median. The whis-
H6 vs. H1, H2, H3 (panel B).
Fig. 2. Effects of MMP-9 haplotypes on plasma TIMP-1 CONCENTRATIONS in the control (Panel A), migraine (Panel B), migraine without aura (MWA; Panel C) and Migraine with
aura (MA; Panel D) groups. The box and whisker plots show range and quartiles. The boxes extend from the 25th percentile to the 75th percentile, with a line at the median. The
whiskers show the highest and the lowest values.
93A. Martins-Oliveira et al. / Journal of Neuroimmunology 252 (2012) 89–94between groups; secondly, we studied only women. We decided to in-
clude only women in our study because the prevalence of migraine is
higher in women than in men (Jensen and Stovner, 2008). The male:fe-
male ratio for migraine among adults varies from 1:2 to 1:3, thus facili-
tating the recruitment of patients for the study. Because we included
only women in the present study, we can not necessarily extrapolate
our ﬁndings to men, especially because there are many differencesFig. 3. Effects of MMP-9 haplotypes on MMP-9/TIMP-1 ratio in the control (Panel A), migraine
groups. The box and whisker plots show range and quartiles. The boxes extend from the 25th p
and the lowest values.between man and women, particularly with respect to hormonal issues;
thirdly, we have not evaluated clinical cardiovascular events in the pres-
ent study or other parameters of the insulin and lipid metabolism that
may affect MMPs in migraine patients (Bernecker et al., 2011). Howev-
er, these limitations require additional studies.
In conclusion, our ﬁndings suggest that the “C L Q” haplotype is
associated with highest MMP-9 levels in migraine patients, possibly(Panel B), migraine without aura (MWA; Panel C) and migraine with aura (MA; Panel D)
ercentile to the 75th percentile, with a line at the median. The whiskers show the highest
94 A. Martins-Oliveira et al. / Journal of Neuroimmunology 252 (2012) 89–94contributing to proteolytic breakdown of the BBB. Patients with this
speciﬁc haplotype may beneﬁt from the use of MMPs inhibitors.
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